Goldenwell Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 17, 2023 at 12:28 pm EDT
Share
Goldenwell Biotech, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.000276 million compared to USD 0.003713 million a year ago. Net loss was USD 0.027084 million compared to USD 0.0268 million a year ago.
For the six months, sales was USD 0.001698 million compared to USD 0.00411 million a year ago. Net loss was USD 0.06069 million compared to USD 0.06018 million a year ago.
Goldenwell Biotech, Inc. is in the development stage whose purpose is research and development, production and sales health cares and supplements products. The Company is offering its products under two categories: Polypeptide Freeze-dried Powder and Solid Tablets Products. The Companyâs products are JI MAI-Bovine Cardiac Vascular Active Peptide, Double Proline AG- three-dimensional (3D) Active Collagen Peptide, Cartilage Peptide-Type II collagen peptide, Se Plus, and Sugar Master. Bovine cardiac vascular active peptide is a protein peptide of vascular homology (amino acid type and its sequence) which made from healthy and fresh bovine cardiac vascular tissues as raw materials. Its DPAG product is designed to be an easily absorbed bioactive collagen. Type II collagen peptide is prepared from Bovine or Pig Cartilage bones by hot water extraction. Its Sugar Master product is made utilizing low temperature extraction techniques to maximize the harvest of bio-actives of plant matter.
GOLDENWELL BIOTECH, INC. 
